HEMOPHILIA: DIAGNOSIS AND INNOVATIVE MANAGEMENT.

Hemophilia is an acquired,X-linked,passive disorder caused by an insufficiency of utilitarian plasma clotting factor VIII (FVIII). In a critical number of cases, the disorder results from a novo mutation. It rarely manifests as an acquired autoimmune process.Research facility thinks about for suspected hemophilia include a total blood cell tally,coagulation ponders, and an FVIII assay. In patients with an established diagnosis of hemophilia, periodic research facility evaluations include screening for the presence of FVIII inhibitors and screening for transfusion-related or transmissible illnesses such as hepatitis and HIV contamination. Estimation of FVIII levels is critical for observing FVIII substitution treatment. Treatment of hemophilia includes prophylaxis, treatment of bleeding episodes, and induction of immune tolerance.Intended for the treatment and rehabilitation of the patients who are taking factor inhibitors and patients have hemophilic synovitis. Treatment for hemophiliacs should ideally be provided by a Hemophilia Day Care center.We discuss innovative management for the prevention of hemophilia through gene therapy,non-replacement therapy,EHL recombinant concentration,etc.we discuss the data from our studies and emerging results from other gene therapy trials in both hemophilia A and B. This analysis will provide evidence and information on the feasibility and data quality/completeness of the hemophilia database to assess the impact of innovative management on hemophilia outcomes in developing countries.We used a statistical method to analyze the data of adult and pediatric patients who come to hemophilia day care center for taking treatment.The data analysis was performed by the data collected monthly at the hemophilia day care center.